With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumesthe more commonly seen end point with MRI.
Oxford, UK- A new imaging study is providing a first hint at the potential for niacin to help with plaque regression when used on top of optimized statin therapy [1]. Writing in the November 3, 2009 issue of the Journal of the American College of Cardiology (JACC), Dr Justin MS Lee (University of Oxford, UK) and colleagues report that 2 g of modified-release nicotinic acid (Niaspan, Abbott Laboratories) daily, on top of statins, resulted in a 1.64 mm2 reduction in carotid wall area on MRI, compared with placebo, in patients with vascular disease and low HDL.
Read full article »
Inside: Imaging
Accredited educational programs,
supported by industry, developed by theheart.org
Dr. Jeroen Bax, on the cusp of publishing a landmark paper to validate the role of MIBG imaging in risk stratifying patients with heart failure, provides a snapshot of his study in this interview from Europace 2009.
Variable rate contrast delivery systems have the potential to improve workflow and patient outcomes by providing a more precise flow of contrast. Watch Dr. Jeffrey Moses and his team as they demonstrate the use of the device in the cath lab in a patient with complex lesions.
Can drug-eluting stents now be considered the standard of care in patients with STEMI undergoing PCI? Can target lesion revascularization be reduced further? What about bleeding? Please join Drs Stone, White, and Harrington as they tackle these and other pressing questions in the treatment of AMI.
As part of his mission to see more financial transparency in medicine, Sen Grassley has asked eight top US medical schools about their policies on ghostwriting.
Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes.
The use of coronary CT angiography in the emergency room can successfully triage at-risk chest-pain patients and can do so faster and less expensively than standard diagnostic testing.
Inflation of the paclitaxel-delivering balloon followed by a bare-metal stent failed a randomized noninferiority test against the Cypher sirolimus-eluting stent in previously untreated coronary lesions.
Now that the US House of Representatives has passed a healthcare reform bill, organized medicine anticipates another votepossibly next weekon a second bill that would rewrite Medicare's controversial sustainable-growth-rate formula for physician reimbursement.
A new postmortem study using high-resolution imaging has found that fractures in drug-eluting stents may be more common than thought. However, the majority of such fractures appear to be low-grade and silent, with likely few clinical implications, say the researchers.
Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.
Coronary plaque burden in patients with acute chest pain increases significantly over two years. A new Harvard study evaluates CTA as a tool to follow the progression.
Obesity and hypertension were major independent risk factors for left atrial enlargement (itself a risk factor for atrial fibrillation) in an observational, population-based study, but obesity was the strongest predictor.
Join Drs Valentin Fuster, Roger Blumenthal, Bob Harrington, Judith Hochman, Sanjay Kaul, Suzanne Oparil, Gregg Stone, Lynne Warner Stevenson, and Bruce Wilkoff as they discuss the results of ARBITER 6-HALTS, the PLATO STEMI subanalysis, the two CHAMPIONs, and CASCADE and tackle the issue of too little, too soon in clinical trials today.
New agents and interventions are paving the way for revised modalities in the management of patients with atrial fibrillation. Join Drs Alpert and Delascio Lopes for a review of the latest findings and options.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.